Nobivac LeuFel

Țară: Uniunea Europeană

Limbă: engleză

Sursă: EMA (European Medicines Agency)

Cumpara asta acum

Prospect Prospect (PIL)
07-10-2021

Ingredient activ:

purified Rp-45 FeLV-envelope antigen

Disponibil de la:

Virbac S.A.

Codul ATC:

QI06AA01

INN (nume internaţional):

Feline leukaemia vaccine (inactivated)

Grupul Terapeutică:

Cats

Zonă Terapeutică:

Inactivated viral vaccines

Indicații terapeutice:

Active immunisation of cats from eight weeks of age against feline leukaemia for the prevention of persistent viraemia and clinical signs of the related disease.

Rezumat produs:

Revision: 3

Statutul autorizaţiei:

Authorised

Data de autorizare:

2017-11-06

Prospect

                                13
B. PACKAGE LEAFLET
14
PACKAGE LEAFLET
NOBIVAC LEUFEL SUSPENSION FOR INJECTION FOR CATS
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
RELEASE, IF DIFFERENT
Marketing authorisation holder and manufacturer responsible for the
batch release
VIRBAC,
1
ère
avenue 2065 m LID
06516 Carros
France
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Nobivac LeuFel suspension for injection for cats
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
Per dose of 1 ml:
ACTIVE SUBSTANCE:
Minimum quantity of purified p45 FeLV-envelope antigen
102 µg
ADJUVANTS:
3% aluminium hydroxide gel expressed as mg Al
3+
1 mg
Purified extract of
_Quillaja saponaria_
10 µg
EXCIPIENTS:
Buffered isotonic solution to 1 ml.
Opalescent liquid.
4.
INDICATION(S)
Active immunisation of cats from eight weeks of age against feline
leukaemia for the prevention of
persistent viraemia and clinical signs of the related disease.
The onset of immunity has been demonstrated from 3 weeks after the
primary vaccination.
After the primary vaccination course, the duration of immunity lasts
for one year.
Following a first booster vaccination one year after the primary
vaccination course, a duration of
immunity of 3 years has been demonstrated.
5.
CONTRAINDICATIONS
None.
15
6.
ADVERSE REACTIONS
A moderate and transient local reaction (<2 cm) is commonly observed
after the first injection. This
local reaction could be a swelling, an oedema or a nodule and resolves
spontaneously within from 3 to
4 weeks at the most. After the second injection, and subsequent
administrations, this reaction is
markedly reduced.,
The transient signs following vaccination such as hyperthermia
(lasting 1 to 4 days), apathy and
digestive disturbances may also be commonly observed.
Pain at palpation, sneezing or conjunctivitis may be noted in rare
cases. This resolves without any
treatment.
Anaphylactic reactions have been reported in very rare cases. In case
of anaphylactic shock,
appropriate symptomat
                                
                                Citiți documentul complet
                                
                            

Caracteristicilor produsului

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Nobivac LeuFel suspension for injection for cats
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Per dose of 1 ml:
ACTIVE SUBSTANCE:
Minimum quantity of purified p45 FeLV-envelope antigen
102 µg
ADJUVANTS:
3% aluminium hydroxide gel expressed as mg Al
3+
1 mg
Purified extract of
_Quillaja saponaria_
10 µg
EXCIPIENTS:
Buffered isotonic solution to
1 ml.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Suspension for injection.
Opalescent liquid.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cats
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Active immunisation of cats from eight weeks of age against feline
leukaemia for the prevention of
persistent viraemia and clinical signs of the related disease.
The onset of immunity has been demonstrated from 3 weeks after the
primary vaccination.
After the primary vaccination course, the duration of immunity lasts
for one year.
Following a first booster vaccination one year after the primary
vaccination course, a duration of
immunity of 3 years has been demonstrated.
4.3
CONTRAINDICATIONS
None.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Vaccinate healthy animals only.
3
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
De-worming at least 10 days prior to vaccination is recommended.
Only feline leukaemia virus (FeLV) negative cats should be vaccinated.
Therefore, a test for presence
of FeLV before vaccination is recommended.
Special precautions to be taken by the person administering the
veterinary medicinal product to
animals
In case of accidental self-injection, seek medical advice immediately
and show the package leaflet or
the label to the physician.
4.6
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
A moderate and transient local reaction (<2 cm) is commonly observed
after the first injection. This
local reaction could be a swelling, an oedema or a nodule and resolves
spontaneously within from 3 to
4 weeks at the most. After the se
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect bulgară 07-10-2021
Caracteristicilor produsului Caracteristicilor produsului bulgară 07-10-2021
Raport public de evaluare Raport public de evaluare bulgară 19-10-2018
Prospect Prospect spaniolă 07-10-2021
Caracteristicilor produsului Caracteristicilor produsului spaniolă 07-10-2021
Raport public de evaluare Raport public de evaluare spaniolă 19-10-2018
Prospect Prospect cehă 07-10-2021
Caracteristicilor produsului Caracteristicilor produsului cehă 07-10-2021
Raport public de evaluare Raport public de evaluare cehă 19-10-2018
Prospect Prospect daneză 07-10-2021
Caracteristicilor produsului Caracteristicilor produsului daneză 07-10-2021
Raport public de evaluare Raport public de evaluare daneză 19-10-2018
Prospect Prospect germană 07-10-2021
Caracteristicilor produsului Caracteristicilor produsului germană 07-10-2021
Raport public de evaluare Raport public de evaluare germană 19-10-2018
Prospect Prospect estoniană 07-10-2021
Caracteristicilor produsului Caracteristicilor produsului estoniană 07-10-2021
Raport public de evaluare Raport public de evaluare estoniană 19-10-2018
Prospect Prospect greacă 07-10-2021
Caracteristicilor produsului Caracteristicilor produsului greacă 07-10-2021
Raport public de evaluare Raport public de evaluare greacă 19-10-2018
Prospect Prospect franceză 07-10-2021
Caracteristicilor produsului Caracteristicilor produsului franceză 07-10-2021
Raport public de evaluare Raport public de evaluare franceză 19-10-2018
Prospect Prospect italiană 07-10-2021
Caracteristicilor produsului Caracteristicilor produsului italiană 07-10-2021
Raport public de evaluare Raport public de evaluare italiană 19-10-2018
Prospect Prospect letonă 07-10-2021
Caracteristicilor produsului Caracteristicilor produsului letonă 07-10-2021
Raport public de evaluare Raport public de evaluare letonă 19-10-2018
Prospect Prospect lituaniană 07-10-2021
Caracteristicilor produsului Caracteristicilor produsului lituaniană 07-10-2021
Raport public de evaluare Raport public de evaluare lituaniană 19-10-2018
Prospect Prospect maghiară 07-10-2021
Caracteristicilor produsului Caracteristicilor produsului maghiară 07-10-2021
Raport public de evaluare Raport public de evaluare maghiară 19-10-2018
Prospect Prospect malteză 07-10-2021
Caracteristicilor produsului Caracteristicilor produsului malteză 07-10-2021
Raport public de evaluare Raport public de evaluare malteză 19-10-2018
Prospect Prospect olandeză 07-10-2021
Caracteristicilor produsului Caracteristicilor produsului olandeză 07-10-2021
Raport public de evaluare Raport public de evaluare olandeză 19-10-2018
Prospect Prospect poloneză 07-10-2021
Caracteristicilor produsului Caracteristicilor produsului poloneză 07-10-2021
Raport public de evaluare Raport public de evaluare poloneză 19-10-2018
Prospect Prospect portugheză 07-10-2021
Caracteristicilor produsului Caracteristicilor produsului portugheză 07-10-2021
Raport public de evaluare Raport public de evaluare portugheză 19-10-2018
Prospect Prospect română 07-10-2021
Caracteristicilor produsului Caracteristicilor produsului română 07-10-2021
Raport public de evaluare Raport public de evaluare română 19-10-2018
Prospect Prospect slovacă 07-10-2021
Caracteristicilor produsului Caracteristicilor produsului slovacă 07-10-2021
Raport public de evaluare Raport public de evaluare slovacă 19-10-2018
Prospect Prospect slovenă 07-10-2021
Caracteristicilor produsului Caracteristicilor produsului slovenă 07-10-2021
Raport public de evaluare Raport public de evaluare slovenă 19-10-2018
Prospect Prospect finlandeză 07-10-2021
Caracteristicilor produsului Caracteristicilor produsului finlandeză 07-10-2021
Raport public de evaluare Raport public de evaluare finlandeză 19-10-2018
Prospect Prospect suedeză 07-10-2021
Caracteristicilor produsului Caracteristicilor produsului suedeză 07-10-2021
Raport public de evaluare Raport public de evaluare suedeză 19-10-2018
Prospect Prospect norvegiană 07-10-2021
Caracteristicilor produsului Caracteristicilor produsului norvegiană 07-10-2021
Prospect Prospect islandeză 07-10-2021
Caracteristicilor produsului Caracteristicilor produsului islandeză 07-10-2021
Prospect Prospect croată 07-10-2021
Caracteristicilor produsului Caracteristicilor produsului croată 07-10-2021
Raport public de evaluare Raport public de evaluare croată 19-10-2018

Vizualizați istoricul documentelor